Table 2 Demographic and clinical characteristics of incident CDI, cases and matched controls

Age, mean (years)

45,9 ± 9,3

45,4 ± 8,8

45,5 ± 8,9

MD – 0,6 (±1,2)

0,64

Gender, N (%)

M

56 (70,1)

116 (73,4)

172 (72,6)

F

23 (29,1)

42 (26,6)

65 (27,4)

Hospitalization (days)^

33,5 ± 26,6

14,2 ± 12,2

20,6 ± 20,3

Antiretroviral Treatment

55 (69,6)

96 (60,8)

151 (63,7)

OR 1,5 (0,8 – 2,8)

0,20

Chronic HCV

39 (49,4)

67 (42,4)

106 (44,7)

OR 1,3 (0,7 – 2,4)

0,31

Acid suppressants

36 (45,6)

51 (32,3)

87 (36,7)

OR 1,8 (1,0 – 3,2)

0,04*

Antineoplastic chemotherapy

9 (11,4)

11 (7,0)

20 (8,4)

OR 1,7 (0,6 – 4,8)

0,25

Previous hospitalization ^§

45 (57,0)

55 (34,8)

100 (42,2)

OR 2,5 (1,4 – 4,5)

0,01*

Antibiotic exposure

71

123

194

OR 2,5 (1,1 – 6,6)

0,02*

Death during hospitalization

11 (13,9)

10 (6,3)

21 (8,9)

Methadone therapy

17 (21,5)

37 (23,4)

54 (22,8)

OR 0,9 (0,4 – 1,8)

0,74

CD4 on admission^

188 ± 237

262 ± 259

238 ± 254

MD 74,3 (±34,8)

0,03*

Charlson score^

6,8 ± 3,4

5,7 ± 3,7

6,1 ± 3,6

MD -1,1 (±0,5)

0,027*

HIV RNA, median

20.610

2.214

3.601

MD -15.935 (±33.975)

0,640

Serum Creatinine on admission (mg/dl)^

1,3 ± 1,8

0,9 ± 0,7

1,1 ± 1,2

MD 1,1 (±0,1)

0,036*

Serum Albumin on admission (g/dl)^

3,0 ± 0,7

3,4 ± 0,7

3,2 ± 0,7

MD 0,4 (±0,1)

<0,001*

Gammaglobulins on admission (g/dl)^

1,6 ± 0,7

1,9 ± 1,0

1,8 ± 0,9

MD 0,2 (±0,1)

0,05*